AMANDA GALLOWAY: Open Payments
NPI 1396764148 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,036 in 158 payments from 33 companies in 2025. Trend: 2023 $651 · 2024 $2,843 · 2025 $3,036
Food & beverage: $3,034Education: $1
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 14 | $361 |
| Bayer Healthcare Pharmaceuticals Inc. | 15 | $269 |
| Xeris Pharmaceuticals, Inc. | 15 | $241 |
| Abbott Laboratories | 8 | $190 |
| Insulet Corporation | 11 | $174 |
| Amgen Inc. | 12 | $172 |
| Lilly USA, LLC | 8 | $136 |
| Madrigal Pharmaceuticals | 5 | $114 |
| ABBVIE INC. | 6 | $106 |
| Dexcom, Inc. | 6 | $106 |
Products named: Kerendia, FREESTYLE LIBRE 3, RECORLEV, Omnipod, JARDIANCE, Ozempic, Wegovy, TEPEZZA.
Industry payments across TX — which companies pay providers there.
